What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HepaCure will be administered in extracorporal dialysis following the treatment of DPMAS and LPE.”In the company’s words, NCT05989958 on ClinicalTrials.gov
- Tested for
- Acute on Chronic Hepatic Failure, Liver Failure, Hepatitis
- Main trialPhase 1/2
- “This is a multicenter, randomized, controlled, open-label phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure(ACLF). Phase 1 is a multicenter, open label study to evaluate the safety and tolerability of single dose and multiple doses of HepaCure with different treatment duration plus DPMAS in ACLF subjects respectively. Phase 2 is a multicenter, randomized and controlled open label study to evaluate…”In the company’s words, NCT05989958 on ClinicalTrials.gov
Other drugs for Liver Failure
- Custodiol-NDr. F. Köhler Chemie GmbH · Phase 3
- TYNADOTESinew Pharma Inc. · Phase 2
- LYG-LIV0001LyGenesis, Inc. · Phase 2
- NTZGenfit · Phase 2
- EGEN-5784eGenesis, INC · Phase 1/2
- TAK-242Yaqrit Ltd · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Sep 2026 | The Safety ,Tolerability and Efficacy Study of HepaCure in Chinese Subjects with Acute-On-Chronic Liver Failure |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026